Partnerships are a key component in the operating playbook of emerging and developing biotechnology companies. Although this year is shaping up as a very big one for deals, according to data from the Biotechnology Industry Organization (BIO) and biopharma consulting firm Campbell Alliance Group, they are not as lucrative for generating cash in the early stages as they once were.